Search Results

Webinar: SRP-9001 Data Update from Studies 101, 102, and 103 (August 2022)

Webinar: SRP-9001 Data Update from Studies 101, 102, and 103 (August 2022)

Webinar: SRP-9001 Micro-Dystrophin Gene Therapy Clinical Update (October 2021)

Webinar: SRP-9001 Micro-Dystrophin Gene Therapy Clinical Update (October 2021)

Webinar: SRP-9001 Micro-Dystrophin Gene Therapy Clinical Update (June 2021)

Webinar: SRP-9001 Micro-Dystrophin Gene Therapy Clinical Update (June 2021)

Investigational Gene Therapy (SRP-9001) Shows Promise in Duchenne Muscular Dystrophy Patients

Investigational Gene Therapy (SRP-9001) Shows Promise in Duchenne Muscular Dystrophy Patients

Clinical Trial: SRP-9001 for Duchenne Muscular Dystrophy (NCT03769116)

Clinical Trial: SRP-9001 for Duchenne Muscular Dystrophy (NCT03769116)

Updates on a trial of SRP-9001 gene transfer therapy in Duchenne muscular dystrophy (DMD)

Updates on a trial of SRP-9001 gene transfer therapy in Duchenne muscular dystrophy (DMD)

Mechanism of Action of SRP-9001, A Gene Therapy For Duchenne Muscular Dystrophy

Mechanism of Action of SRP-9001, A Gene Therapy For Duchenne Muscular Dystrophy

Webinar: ENVISION Study Update with Sarepta Therapeutics

Webinar: ENVISION Study Update with Sarepta Therapeutics

Sarepta's SRP-9001 Gene Therapy for Duchenne Muscular Dystrophy Faces FDA Advisory Committee Review

Sarepta's SRP-9001 Gene Therapy for Duchenne Muscular Dystrophy Faces FDA Advisory Committee Review

Clinical Trial Experiences Managing Adverse Events in Gene Therapy for DMD

Clinical Trial Experiences Managing Adverse Events in Gene Therapy for DMD

Webinar: Casimir's Duchenne Video Assessment (DVA) ARISE Study [August 2022]

Webinar: Casimir's Duchenne Video Assessment (DVA) ARISE Study [August 2022]

Sarepta's SRP-9001, Gene Therapy, for Duchenne Muscular Dystrophy Faces FDA Decision Delay

Sarepta's SRP-9001, Gene Therapy, for Duchenne Muscular Dystrophy Faces FDA Decision Delay